Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib, Bendamustine, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT02095834Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2014
- Primary completion
- Jan 2021
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of carfilzomib in multiple myeloma (MM), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Maximum Tolerated Dose at 28 days and Recommended Phase 1b Dose up to 6 years. Started Apr 2014; status: completed.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02095834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02095834.